Understanding Glucocorticoids and Their Impact

Introduction to Glucocorticoids

Glucocorticoids are steroid hormones that have been utilized for over 65 years to manage inflammatory conditions, such as rheumatoid arthritis. Their effectiveness in reducing inflammation is widely recognized; however, the side effects associated with prolonged use have received less attention until recently.

Common Side Effects of Glucocorticoids

The adverse effects primarily affect bone and muscle metabolism. Notable complications include:

– Osteoporosis
– Osteonecrosis
– Myopathy
– Sarcopenia

Additional risks encompass diabetes, obesity, dyslipidaemia, skin atrophy, hypertension, alterations in growth and sex hormones, glaucoma, cataracts, delayed wound healing, and an increased susceptibility to infections. Osteoporosis, characterized by the loss of bone tissue, poses a significant risk for patients on long-term glucocorticoid therapy.

Glucocorticoid-Induced Osteoporosis

Prevalence and Undiagnosed Cases

Glucocorticoid-induced osteoporosis is often underdiagnosed and inadequately managed within the healthcare system. Approximately 80% of all bone fractures, particularly in the spine, proximal femur, and ribs, are attributed to unmonitored glucocorticoid use. Around 25% of treated patients may experience a fracture within the first year, and this number escalates to 50% within 5 to 10 years.

Challenges in Treatment

Despite the significant risks, therapeutic interventions are frequently delayed. This may be due to insufficient research regarding drug mechanisms and a lack of accessible clinical information. The key to minimizing adverse effects lies in reducing both the dosage and duration of glucocorticoid treatment.

Physiological Role of Natural Glucocorticoids

Natural glucocorticoids exist in the body at low levels, playing vital roles in electrolyte balance, fluid control, homeostasis, fuel metabolism, and immune responses. They also aid in bone formation and maintenance, as well as calcium regulation in the kidneys and intestines. However, pharmacological doses disrupt these processes, leading to decreased bone mineralization and accelerated bone mass loss, particularly within the first 6 to 12 months of treatment.

High-Risk Patient Profiles

Patients at the highest risk for glucocorticoid-induced osteoporosis include those who:

– Undergo treatment longer than 3 months
– Receive high doses of glucocorticoids or combined therapies with other steroids
– Are over 60 years of age
– Have a low Body Mass Index (BMI)
– Exhibit low Bone Mineral Density (BMD)

Prevention Strategies for Osteoporosis

Initial Evaluations and Monitoring

To mitigate risks, patients should undergo a thorough evaluation of their bone health status before commencing glucocorticoid therapy. This assessment should include dietary calcium intake, sun exposure, physical activity levels, and other risk factors. Additional testing for renal and hepatic function, serum 25-hydroxyvitamin D, calcium, and sex hormone levels is also advisable. Continuous monitoring throughout treatment is essential; a height loss of 3-5 cm may indicate vertebral fractures requiring medical attention.

Concurrent Intervention and Supplements

Preventive measures for glucocorticoid-induced osteoporosis should commence simultaneously with glucocorticoid therapy and continue without interruption. Studies suggest that Vitamin D and Calcium supplements may provide beneficial effects. Additionally, prescription medications specifically targeting glucocorticoid-induced osteoporosis are available, though research on these drugs is limited and they may pose health risks.

Medications for Osteoporosis Management

The following five major classes of drugs are utilized to manage glucocorticoid-induced osteoporosis:

– **Bisphosphonates**: Including Alendronate, Risedronate, Etidronate, and Zoledronic acid, these medications have demonstrated increases in BMD and reductions in fracture risk, although most studies focus on women with postmenopausal osteoporosis.

– **Teriparatide**: This osteoanabolic hormone may benefit patients taking glucocorticoids alongside other steroids, with evidence of improved BMD and lower fracture risk primarily in postmenopausal women.

– **Hormone Replacement Therapy**: While addressing hypogonadism-related bone loss and fractures, this treatment carries significant risks and should only be considered if other options are ineffective.

– **Raloxifene**: Similar to other treatments, increased BMD and decreased fracture risk have been observed mainly in postmenopausal women.

– **Denosumab**: This medication has shown positive effects on hip and spine BMD in some studies.

Future Directions in Research

Ongoing research focuses on the development of new oral glucocorticoids that aim to minimize side effects in tissues other than bone and reduce hormonal impacts that contribute to glucose intolerance, diabetes, dyslipidaemia, and obesity—areas that have not been extensively studied.

Related Topics of Interest

– Osteoporotic Fracture and Bisphosphonates: Long-Term Risks
– The Role of Statins in Osteoporosis Prevention
– Impact of Carotenoids on Osteoporotic Fractures
– Risks Associated with Stopping Osteoporosis Treatment
– High Blood Glucose Levels and Osteoporotic Fracture Risk
– The Influence of a High Soy Diet on Osteoporotic Fractures in Breast Cancer Survivors
– Monitoring and Improving Bone Mineral Density in Osteoporosis

References

Seibel, M.J. et al. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. The Lancet Diabetes and Endocrinology. Available from: http://www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70045-7/fulltext. Last accessed: July 2013.

Written by Julia Yusupova.